Free Trial
NASDAQ:XNCR

Xencor Q1 2026 Earnings Results & Report

Xencor logo
$39.39 +0.80 (+2.07%)
Closing price 11/10/2026 04:00 PM Eastern
Extended Trading
$39.40 +0.01 (+0.03%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xencor missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 6, 2026. The company reported EPS of -$1.71 versus the -$0.7468 consensus estimate, while revenue of $4.52 million fell short of the $27.86 million estimate by $23.34 million. Revenue decreased 86.2% year over year.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Xencor EPS Results

Actual EPS
-$1.71
Consensus EPS
-$0.7468
Beat/Miss
Missed by -$0.9632
One Year Ago EPS
-$0.66
EPS Beat Rate
6 of last 8 quarters

Xencor Revenue Results

Actual Revenue
$4.52 million
Expected Revenue
$27.86 million
Beat/Miss
Missed by -$23.34 million
YoY Revenue Growth
-86.20%

Xencor Q1 2026 Earnings FAQ

Xencor (NASDAQ:XNCR) reported earnings of -$1.71 per share for Q1 2026, missing the consensus estimate of -$0.7468. The report was announced on Wednesday, May 6, 2026.

Xencor reported revenue of $4.52 million for Q1 2026, against a consensus estimate of $27.86 million.

Xencor Earnings Headlines

Xencor (NASDAQ:XNCR) Stock Rating Raised to "Buy" at Wall Street Zen
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
Xencor (XNCR) Gets a Buy from Canaccord Genuity
See More Xencor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email.

About Xencor

Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target.

Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets. The company is headquartered in Monrovia, California, and its collaborations extend its work with partners beyond the United States.

Founded in 1997, Xencor is led by co-founder and Chief Executive Officer Bassil I. Dahiyat, Ph.D. Its focus is on developing and partnering antibody medicines rather than operating as a broad commercial drug manufacturer.

View Xencor Profile